Published in Blood Weekly, September 16th, 1996
Currently, recombinant human hemoglobin (Optro) is in clinical trials to evaluate its use in a setting of intraoperative blood loss, noted Michael P. Doyle, Somatogen, Inc., Boulder, Colorado, while addressing participants attending the VI International Symposium on Blood Substitutes, held August 5-7, 1996, at McGill University, in Montreal, Quebec, Canada.
Somatogen recently had developed an animal model to determine the efficacy of their product during resuscitation from hemorrhagic shock.
"The hemorrhage protocol used in this study is sufficient to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.